Kwality Pharmaceuticals Ltd (KPL) — Voting Results | 2 September 2026

2 September 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

All resolutions passed at 43rd AGM with requisite majority

🔄 What Changed

Adoption of audited standalone and consolidated financial statements for FY2026

💡 Investor Takeaway

Shareholders approved all key governance and financial items, confirming board continuity and auditor remuneration.

Kwality Pharmaceuticals Limited held its 43rd Annual General Meeting on August 31, 2026, where shareholders approved all six resolutions including the adoption of audited standalone and consolidated financial statements for FY2026, appointment of directors, and ratification of cost auditors' remuneration. The meeting concluded at 12:35 PM after starting at 12:00 PM, with voting conducted electronically and via postal ballot. Scrutinizer Rishi Mittal & Associates confirmed compliance with regulatory requirements for e-voting and postal ballot scrutiny.

📄 View Original Announcement (PDF)

📊 Stock Analysis — KPL ✨ Ask AI About This

About Kwality Pharmaceuticals Ltd (KPL)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹3,763.5 CrP/E: 46.4ROE: 24.4%ROCE: 25.4%

View full KPL stock details →

📡 Get AI alerts when KPL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KPL — Free

💡 Ask AI about this filing

"What was the exact vote percentage for director appointments?""How does remuneration compare to industry peers?""What are the audited financial results for FY2026?"

Ask AI Free →

📊 More KPL filings

Announcement — 28 September 2026Kwality Pharmaceuticals Ltd announced that its trading window will close on October 1, 2026, remaini...
🟡 Board Meeting — 31 August 2026Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026 via video conference, with all director...
🟡 concall transcript — 30 June 2026Kwality Pharmaceuticals reported Q1 FY27 results with oncology revenue at 20% of total, down from 26...
🟡 concall transcript — 31 March 2026Kwality Pharmaceuticals reported FY26 revenue of INR503 crores (up 36% YoY) and PAT of INR67 crores ...

See all KPL filings →

🔥 Also filed on 2 September 2026

WAAREEENERWaaree Energies LtdAnnual Report PEARLPOLYPearl Polymers LtdAnnual Report 544627Purple Wave Infocom LtdAnnual Report 544437Marc Loire Fashions LtdAnnual Report RTNINDIARattanIndia Enterprises LtdAnnual Report 544596Safecure Services LtdAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KPL files new disclosures

Track KPL filings, board meetings, and corporate actions. Free email alerts at 5 PM.